Retirement Systems of Alabama increased its position in Zoetis Inc. (NYSE:ZTS) by 2.3% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 232,730 shares of the company’s stock after buying an additional 5,188 shares during the period. Retirement Systems of Alabama’s holdings in Zoetis were worth $11,045,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Renaissance Technologies LLC increased its position in shares of Zoetis by 398.6% in the first quarter. Renaissance Technologies LLC now owns 1,413,100 shares of the company’s stock worth $62,643,000 after buying an additional 1,129,700 shares in the last quarter. Cullen Frost Bankers Inc. increased its position in shares of Zoetis by 0.7% in the second quarter. Cullen Frost Bankers Inc. now owns 347,368 shares of the company’s stock worth $16,486,000 after buying an additional 2,470 shares in the last quarter. Legal & General Group Plc increased its position in shares of Zoetis by 0.9% in the first quarter. Legal & General Group Plc now owns 2,104,616 shares of the company’s stock worth $93,293,000 after buying an additional 18,063 shares in the last quarter. York Capital Management Global Advisors LLC acquired a new position in shares of Zoetis during the first quarter worth $49,823,000. Finally, Raymond James Trust N.A. increased its position in shares of Zoetis by 5.0% in the second quarter. Raymond James Trust N.A. now owns 5,909 shares of the company’s stock worth $281,000 after buying an additional 281 shares in the last quarter. Institutional investors and hedge funds own 93.12% of the company’s stock.
Zoetis Inc. (NYSE:ZTS) traded down 0.25% during trading on Wednesday, hitting $52.18. The company had a trading volume of 2,608,084 shares. Zoetis Inc. has a one year low of $38.26 and a one year high of $52.64. The stock has a market capitalization of $25.83 billion, a PE ratio of 40.64 and a beta of 1.01. The stock has a 50-day moving average of $51.28 and a 200-day moving average of $48.65.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $0.49 EPS for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.05. Zoetis had a net margin of 13.15% and a return on equity of 77.58%. The business earned $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the prior year, the company earned $0.43 EPS. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. On average, equities analysts anticipate that Zoetis Inc. will post $1.91 EPS for the current year.
ZTS has been the topic of a number of research analyst reports. Citigroup Inc. downgraded Zoetis from a “buy” rating to a “neutral” rating and lifted their price target for the company from $46.00 to $50.00 in a report on Friday, June 10th. They noted that the move was a valuation call. Jefferies Group reiterated a “buy” rating and set a $58.00 price target (up previously from $57.00) on shares of Zoetis in a report on Tuesday, June 14th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $53.00 price target on the stock in a report on Wednesday, June 15th. Guggenheim reiterated a “buy” rating and set a $60.00 price target on shares of Zoetis in a report on Monday, July 18th. Finally, Barclays PLC lifted their price target on Zoetis from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $55.27.
In other news, Director Michael B. Mccallister acquired 2,000 shares of the stock in a transaction that occurred on Tuesday, September 6th. The stock was acquired at an average price of $51.34 per share, for a total transaction of $102,680.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Heidi C. Chen sold 32,097 shares of the company’s stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $50.98, for a total transaction of $1,636,305.06. Following the completion of the sale, the insider now owns 46,060 shares of the company’s stock, valued at approximately $2,348,138.80. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by corporate insiders.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.